The neurotransmitter serotonin (5-HT) controls a broad range of biological functions that are disturbed in affective disorder. In the brain, 5-HT production is controlled by tryptophan hydroxylase 2 (TPH2). In order to assess the possible contribution of TPH2 genetic variability to the etiology of bipolar affective disorder (BPAD), we systematically investigated common and rare genetic variation in the TPH2 gene through a sequential sequencing and SNP-based genotyping approach. Our study sample comprised two cohorts of bipolar affective disorder from Germany and Russia, totalling 883 patients and 1,300 controls. SNPs located in a haplotype block covering the 5' region of the gene as well as a rare non-synonymous SNP, resulting in a Pro206Ser substitution, showed significant association with bipolar disorder. The odds ratio for the minor allele in the pooled sample was 1.5 (95% C.I. 1.2 -1.9) for rs11178997 (in the 5'-associated haplotype block) and 4.8 (95% C.I. 1.6 -14.8) for rs17110563 encoding the Pro206Ser substitution. Examination of the functional effects of TPH2 Pro206Ser provided evidence for a reduced thermal stability and solubility of the mutated enzyme, suggesting reduced 5-hydroxytryptamine (serotonin) production in the brain as a pathophysiological mechanism in bipolar affective disorder.
Introduction
Bipolar affective disorder (BPAD) is a severe psychiatric disorder characterized by episodes of mania and depression with a lifetime prevalence of 1.3-1.6% (1) in all human populations.
The occurrence of at least one manic episode distinguishes BPAD from major depressive disorder (MDD), another common affective disorder. Both BPAD and MDD share depressive symptoms as a common liability factor and a substantial percentage of patients die from suicide. The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has been shown to influence a broad range of behavioural functions that are disturbed in affective disorder, including the control of mood, sleep-wake cycle, appetite, sexual behaviour and cognition (2, 3) . Decreased concentrations of the 5-HT metabolite 5-hydroxyindole acetic acid in cerebrospinal fluid and brain tissues of depressed individuals and suicide victims/attempters strongly suggests a dysregulation of serotonergic neurotransmission in affective disorder (2, 4, 5) . Further, most antidepressant drugs (e.g. serotonin-selective reuptake inhibitors and tricyclic antidepressants) exert their effect by increasing levels of extracellular 5-HT by inhibiting its reuptake or blocking its metabolism. It is therefore likely that naturally occurring variants of genes involved in the regulation of 5-HT levels could play a role in the at Pennsylvania State University on February 20, 2013 http://hmg.oxfordjournals.org/ Downloaded from development of affective disorder. A very strong candidate in this respect is the gene for the recently identified brain-specific isoform of tryptophan hydroxylase (TPH), designated TPH2, which is the rate-limiting enzyme in the biosynthesis of 5-HT in neural tissue (6) . In fact, recent studies have provided preliminary evidence for an involvement of TPH2 variants in MDD and BPAD (7) (8) (9) (10) (11) (12) (13) as well as in suicide (10, (13) (14) (15) . With the exception of Zhang et al. (9) , who reported the Arg441His missense mutation in MDD, no genetic variants of obvious functional relevance could be identified up to now.
The aim of our study was to investigate the possible contribution of genetic variants of TPH2 to the development of BPAD. On the one hand we made use of haplotype tagging SNPs as provided by the International HapMap Project, to test for the contribution of common variants. Since it is not clear to what extent rare variation (i.e. ≤ 1% minor allele frequency) -which is under-represented in common databases -might have an impact on BPAD, we also re-sequenced the coding region of the TPH2 gene in 182 chromosomes. One rare, nonsynonymous SNP in exon 6 (resulting in Pro206Ser) was identified and also included in the study.
We show that a common haplotype block covering the 5' region of the gene and the rare non-synonymous change are associated with BPAD in two samples of German and Russian origin. Further, we present comprehensive functional investigations of mutated TPH2 (Pro206Ser) that strongly suggest that this is one of the first genetic variants of pathophysiological relevance identified in BPAD so far.
Results
In the present study, we systematically investigated TPH2 variability in two cohorts with BPAD. We selected 12 haplotype tagging (ht)SNPs that captured all haplotypes at a population frequency >5%. In addition, we included two SNPs (rs11178997 and rs11178998)
at Pennsylvania State University on February 20, 2013 http://hmg.oxfordjournals.org/ Downloaded from from the 5'-regulatory and 5'-untranslated region. Apart from these frequent SNPs that are best suited to detect common susceptibility variants, we aimed to include rare, coding variants that tend to be under-represented in the common databases and that are not adequately tested for by using HapMap data alone. Such infrequent non-synonymous variants may well be disease-relevant and highly penetrant, as demonstrated by the Arg441His variant described by Zhang et al. (9) . We therefore re-sequenced the complete coding region (11 exons) in a total of 45 BPAD patients of German descent and 46 population-based control individuals, originating from various European countries proportional to their relative population size (16) . The only non-synonymous change was found in exon 6 (c.757 C->T), giving rise to a substitution of a proline in position 206 of the TPH2 protein with a serine (after submission to dbSNP now known as rs17110563). We included rs17110563 in our study and eventually genotyped a set of 15 SNPs in two patient-control samples with BPAD.
In the first sample, comprising 636 BPAD patients and 1,070 population-based controls of German descent, we found significant association with three SNPs that are located in haplotype block 1, which covers part of the 5' regulatory region and exons 1 and 2 ( Table   1 ). The minor alleles of SNPs rs11178997, rs11178998, and rs7954758 were significantly overrepresented in BPAD patients as compared to controls (p=0.0039-0.0051, O.R. 1.5). Table 1 ). For one of these SNPs, rs11178997, Scheuch et al. (17) recently demonstrated that the A-allele reduces TPH2 transcriptional activity in serotonergic neurons from rat raphe nuclei and in human small cell lung carcinoma cells. In our German BPAD sample, genotype distributions for the associated SNP rs11178997 (p=0.0047) showed an O.R. of 1.36 for TA-heterozygous individuals, and 4.00 for homozygous risk-allele carriers (Table 2) . The rare non-synonymous SNP rs17110563 also showed association: 9 out of 636 BPAD patients were heterozygous for Pro206Ser, compared to only 3 out of 1,070 controls (p=0.0066, O.R. 5.1). We noticed that eight out of nine (88.9%) Pro206Ser heterozygous BPAD patients had a strong family history for affective disorder with multiple affected family members. The homozygous wildtype individuals, by contrast, comprised only 66.5% family history positive patients. Strikingly, when we looked up information for the three heterozygous individuals in our population-based control sample, we found that one was affected with MDD and had a strong family history of affective disorder (mother and one uncle Bipolar I, grandfather MDD). When we excluded this individual and reanalysed the sample, the O.R. for the rs17110563 CT genotype increased from 5.1 to 7.7 and the p-value decreased from 0.0066 to 0.0021 (Table 2 ). For three of the heterozygous patients, we had DNA of additional family members available that allowed us to study the segregation of the Ser206 variant in these families ( Figure 1 ). Our results are suggestive of non-random cosegregation of the Ser206 (T-allele) variant with affective disorder. In each family, the parent that would be expected to carry the mutation, in fact is a carrier (Figure 1 Since TPH2 had been reported to be associated with suicidality, we subdivided the German BPAD sample (for which information on this symptom was available) into a group that had experienced suicidal ideation and a group without suicidal thoughts and tested for association with the four BPAD-associated SNPs (Table 3 ). The comparison of the group of patients with suicidal ideation against controls produced almost identical O.R. for the three SNPs in the 5' region (rs11178997, rs11178998, rs7954758) as the group of patients without suicidal ideation against controls ( Table 3 ). The frequency of the non-synonymous SNP appears to be higher in the group with suicidal ideation. We also compared the suicidal ideation versus no suicidal ideation groups directly, and found no significant difference between these two groups. These results suggest that both subgroups contribute similarly to the association finding and that there is no specific effect of the associated TPH2 SNPs on suicidal ideations.
In an attempt to replicate our results from the German sample, we tested the 15 SNPs in an independent, but smaller sample from Russia, consisting of 247 BPAD patients and 230 controls. We observed very similar overrepresentations of risk-alleles in both samples ( Table   1 ). The three SNPs in the 5'-region showed a non-significant trend (p=0.067-0.085), and heterozygosity for the rare, non-synonymous SNP occurred 4 times in the patients and once in the controls (p=0.21). Since there were no significant differences between SNP allele frequencies among German and Russian controls, we decided to combine the two samples to increase statistical power. As shown in Tables 1 and 2 , the significance levels for the associated SNPs increased in the combined sample.
Pro206 is part of a highly conserved domain in all the aromatic amino acid hydroxylases (18).
We have recently generated a homology-based model of human TPH2 based on the crystal structure of the related enzyme tyrosine hydroxylase (TH) (19). Inspection of the wild type (WT) and mutant enzymes ( location in a conserved region of the protein, and the substitution of the hydrophobic imino acid proline with the polar serine residue prompted us to assume that it might be a functionally relevant mutation that in itself confers a disease-risk by changing the functional properties of TPH2. We therefore produced WT (TPH2 Pro206) and the TPH2 Pro206Ser mutant in Escherichia coli and human embryonic kidney (HEK293) cells and compared their expression levels, solubilities, thermal stabilities, secondary structure, and catalytic properties (Fig. 2 , Table 4 ). We also compared the properties of the Pro206Ser TPH2 mutant with the Arg441His variant, which has been reported to be strongly associated with MDD in a US American sample, has an 80% loss-of-function in serotonin production in PC12 cells, (9) , and recently has been shown to have strongly reduced thermal stability and solubility in vitro (19).
While Arg441His was not observed in any of the 2,183 individuals studied here (and therefore supposedly represents a locally confined founder-mutation), we tested the effect of this mutation using the same methods as for Pro206Ser and compared the relative effects of the mutations. TPH2 Pro206Ser had similar catalytic activity (V max ) compared to the WT (Table   4 ), but had decreased solubility ( Fig. 2b ) and thermal stability. At 37 o C, 50 o C and 55 o C, the rate of TPH2 Pro206Ser inactivation was 3-6-fold higher than for the WT enzyme (Fig. 2c, data not shown for 50°C). In comparison, the TPH2 Arg441His had reduced catalytic activity (V max ) compared to the wild-type, and its solubility and thermal stability was even lower than for the Pro206Ser mutant (Table 4 and (19)).
Given that all Pro206Ser mutation carriers observed in the course of our study were heterozygous, we also wanted to mimic this situation by co-expressing equimolar amounts of In order to examine this possibility in further detail, we also employed an alternative experimental system where the WT and mutated proteins were in vitro transcribed and translated either alone or in combination (Table 4 pmol/min/mg for the Arg441His/WT mixture, compared to an average value of 2.0 pmol/min/mg. These values are consistent with a mild dominant negative effect of the Pro206Ser mutation and a moderate negative effect of the Arg441His mutation.
Discussion
Our overall genetic and biochemical data suggest that genetic variation of TPH2 is involved in the etiology of BPAD. At least two independent risk-conferring variants are present in our samples: a rare variant, rs17110563 (MAF <<1% in controls), encoding a Pro206Ser substitution, and a more frequent haplotype block of at least 3 kb size (including rs11178997, MAF approx. 6%) spanning a genomic region of putative regulatory relevance. A strength of our study, is that it independently shows the same effect of both risk-conferring variants in two different BPAD samples. While these results are encouraging, replication studies in other independent samples will be necessary to confirm our finding. We are not aware of any other published study that has tested rs17110563 in BPAD or other neuropsychiatric disorders. On the other hand, rs11178997 had previously been tested for association with BPAD in the NIMH wave 3 pedigrees, but failed to show evidence there (13) . In this study, however, only 33 families were informative for marker rs11178997, with the consequence of low power to detect an association of the magnitude observed in our study. Another recent study (11) investigated this SNP in Swedish MDD and BPAD samples.
Rs11178997 was significantly associated with MDD (135 patients/ 364 controls), however
showing an under-representation of allele A (which is a risk-allele for BPAD in our study).
The BPAD sample (182 patients/ 364 controls) was not significantly associated with rs11178997 (11). Interestingly, however, the A-allele was overrepresented in the Swedish BPAD patients (7% in patients, 5% in controls; p=0.16) which is a distribution comparable to the one seen in our German and Russian BPAD samples (8.6% in the German and Russian BPAD patients, 5.9% in controls; p=0.00046; Table 1 ).
Overlapping with the submission of our study for publication, Scheuch et al. (17) reported results of functional studies investigating the effect of TPH2 promoter polymorphisms on transcriptional activity in serotonergic neurons from rat raphe nuclei and human small lung carcinoma cells. Interestingly, they found that the A-allele of rs11178997, which is associated with BPAD in our study, significantly reduces TPH2 transcriptional activity by 22% in serotonergic raphe neurons and 7% in lung carcinoma cells. These data suggest that A/rs11178997 may be the functionally relevant variant underlying the association of a haplotype block in the 5'-region of the TPH2 gene with BPAD in our study. expressed together, the specific activity of the hybrid protein is 21-88 % lower than anticipated from their average values (negative interallelic complementation) (25) . One mechanism that can explain the decreased activity of PAH and TPH is a destabilization of the heterotetrameric enzymes caused by an unstable subunit. The Pro206Ser and Arg441His variants are both unstable forms of TPH2 (Table 4 and Fig. 2 ). More detailed studies are required to determine the exact molecular mechanisms of such a destabilization of heterotetramers and whether this also occurs in the intact human brain. However, as 5-HT is essential for brain development, even a moderate transient deficiency of this transmitter could lead to permanent alterations of brain function (26).
In conclusion, our results provide evidence that both common and rare variants in TPH2 contribute to BPAD within the same population. Pro206Ser appears to be an infrequent susceptibility variant with a relatively high penetrance, as indicated by its large O.R. (6.5 in the combined German/Russian BPAD sample), its presence in patients with a positive family history of affective disorder, and by its co-segregation with affective disorder in three families tested by us. Our study supports the notion that re-sequencing studies to detect such lowfrequency/high penetrance variants are still needed in genetically complex diseases such as BPAD, and that detection of such variants should complement HapMap-based investigation of common variation to identify the full spectrum of susceptibility variants present at a given locus. 
Material and Methods

German and Russian patient and control samples, recruitment and phenotpye characterization
For all patient and control individuals, written informed consent was obtained prior to study (27) based on all available information, including a structured interview (SCID-I, 28), medical records, and the family history method. We also used the OPCRIT (29) system to obtain detailed polydiagnostic documentation of symptoms.
Fifty-three percent of the patients were female, 47 % male. The mean age was 43.7 ± 13.1 years (median age 43.0), and the mean age-of-onset was 27.5 ± 10.7 years (median age-ofonset 25.0). All individuals and their parents were of German descent.
The German control sample consisted of 1,070 population-based individuals, 51.5% were females, 48.5% were males. The mean age was 48.4 ± 15.5 years (median age 48.0). The control individuals were questioned for a history of psychiatric disorder. Five individuals had a history of bipolar affective disorder and were excluded from the analysis. All individuals were German. 74 (6.8%) patients had one or more non-German grandparent originating from Europe, the Americas, former Soviet Union, or the Middle East.
The Russian BPAD sample consisted of 247 DSM-IV diagnosed patients with bipolar I disorder, following the same diagnostic procedure as described for the German patient 
Expression and purification of P206S
The Pro206Ser mutation was introduced in TPH2 cDNA using the Quik Change site directed mutagenesis kit (Stratagene, La Jolla, California) using primers from Sigma (forward [5' AATTATGGTCAGTCCATTCCCAGGGTG], reverse [5'CACCCTGGGAATGGACTGACCATATTT] . The sequences of all TPH expression clones were verified by DNA sequencing. Expression and purification of WT, Pro206Ser, and Arg441His TPH2 as N-terminal 6xHis-maltose-binding protein (MBP) fusion proteins in E.
coli, followed by cleavage with tobacco etch virus protease (TEV) was performed as described (19). Their relative solubility of the proteins was determined after the cells had been harvested by centrifugation at 4,000 x g for 20 min at 4 °C (18).
Immunostaining
Extracts of bacteria and mammalian cells and purified proteins were analyzed by SDS-PAGE, transferred to a nitrocellulose membrane and immunostained. The primary goat polyclonal TPH2 antibody ab 40846 from Abcam (Cambridge, UK) was applied at a 1:2000 dilution and the secondary donkey anti-goat antibody ab 6566 from Abcam was applied at a 1:5000 dilution. Detection was made by enhanced chemiluminescence and band intensities was measured using a camera and Quantity One software provided by Bio-Rad, (Hercules, CA, USA).
Enzyme assay
TPH activity was assayed at 30 ºC in a standard reaction mixture (100 µL final volume) containing 40 mM NaHepes, pH 7.0, 0.05 mg/mL catalase, 10 µM ferrous ammonium sulfate, 2.5 mM dithiothreitol, 100 µM L-tryptophan (L-Trp), and 250 µM tetrahydrobiopterin, 
Measurement of temperature stability
Enzyme samples (3 µM) in 400 mM NaHepes, pH 7.0, were incubated at 37, 50 or 55 ºC for up to 1 h and then assayed for TPH activity. The data were fitted with exponential decay curves and rate constants were calculated using equation (1) E t = E 0 e -kt + a, where E 0 is the initial enzyme activity, E t is the activity at time t, k is the decay rate constant, and a represents an apparent plateau value. Thermal stability of the Pro206Ser mutant was also determined using circular dichroism spectroscopy as described (19).
Expression of TPH2 in mammalian cells
Human embryonic kidney (HEK A293) cells were transfected with the pcDNA5-TPH2 expression vector (WT, Pro206Ser and Arg441His) using lipofectamine (Gibco) as described by the manufacturer, and the proteins were expressed as described. The cells were harvested after 48 h, the lysed cells were centrifuged (14 000 rpm at 4 o C for 10 min in an Eppendorf microcentrifuge) and the crude cell extracts were kept at -80 o C until used for SDS/ PAGE/immunoblotting and assay of enzyme activity.
In vitro transcription and translation of TPH2
Using a commercial rabbit reticulocyte coupled transcription and translation system (Promega) WT and mutant TPH2 were expressed either alone or in a 50/50 mixture of WT and mutant protein, using 1 µg of total plasmid DNA per reaction and 1 h reaction time.
Using [
35 S] methionine labelling, the conditions were optimized to achieve identical production of the proteins which were subjected to gel filtration before activity assays were 
Molecular modeling/prediction analysis
A homology model of TPH2 was prepared using the crystal structure of tetrameric tyrosine hydroxylase (TH) (45% sequence identity) and the SWISS-MODEL automated protein homology-modeling server. The optimal conformations of the Pro206Ser mutant was determined as described (19).
polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. were incubated at 37 o C or 55°C and residual TPH2 activity (in % of initial activity at t 0 ) was assayed every 1-2 min. See Table 4 for a summary of enzyme properties. 
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